Rapamycin resistance is linked to defective regulation of Skp2

Hana Totary-Jain, Despina Sanoudou, Cula N. Dautriche, Hillary Schneller, Lester Zambrana, Andrew R. Marks

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) plays a role in controlling malignant cellular growth. mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials. However, a significant number of tumors are rapamycin resistant. In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin. RNA interference (RNAi)-mediated silencing of Skp2 in human tumor cells increased their sensitivity to rapamycin in vitro and inhibited the growth of tumor xenografts in vivo. Our findings suggest that Skp2 levels are a key determinant of antitumor responses to mTOR inhibitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamycin as well as Skp2 silencing strategies for therapeutic purposes.

Original languageEnglish
Pages (from-to)1836-1843
Number of pages8
JournalCancer Research
Volume72
Issue number7
DOIs
Publication statusPublished - 1 Apr 2012
Externally publishedYes

Fingerprint

Sirolimus
Neoplasms
Ubiquitin-Protein Ligase Complexes
Pharmacogenetics
Growth
RNA Interference
Heterografts
Down-Regulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Totary-Jain, H., Sanoudou, D., Dautriche, C. N., Schneller, H., Zambrana, L., & Marks, A. R. (2012). Rapamycin resistance is linked to defective regulation of Skp2. Cancer Research, 72(7), 1836-1843. https://doi.org/10.1158/0008-5472.CAN-11-2195

Rapamycin resistance is linked to defective regulation of Skp2. / Totary-Jain, Hana; Sanoudou, Despina; Dautriche, Cula N.; Schneller, Hillary; Zambrana, Lester; Marks, Andrew R.

In: Cancer Research, Vol. 72, No. 7, 01.04.2012, p. 1836-1843.

Research output: Contribution to journalArticle

Totary-Jain, H, Sanoudou, D, Dautriche, CN, Schneller, H, Zambrana, L & Marks, AR 2012, 'Rapamycin resistance is linked to defective regulation of Skp2', Cancer Research, vol. 72, no. 7, pp. 1836-1843. https://doi.org/10.1158/0008-5472.CAN-11-2195
Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR. Rapamycin resistance is linked to defective regulation of Skp2. Cancer Research. 2012 Apr 1;72(7):1836-1843. https://doi.org/10.1158/0008-5472.CAN-11-2195
Totary-Jain, Hana ; Sanoudou, Despina ; Dautriche, Cula N. ; Schneller, Hillary ; Zambrana, Lester ; Marks, Andrew R. / Rapamycin resistance is linked to defective regulation of Skp2. In: Cancer Research. 2012 ; Vol. 72, No. 7. pp. 1836-1843.
@article{2c4c1464b35540f2b03ff150a95f0818,
title = "Rapamycin resistance is linked to defective regulation of Skp2",
abstract = "The mammalian target of rapamycin (mTOR) plays a role in controlling malignant cellular growth. mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials. However, a significant number of tumors are rapamycin resistant. In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin. RNA interference (RNAi)-mediated silencing of Skp2 in human tumor cells increased their sensitivity to rapamycin in vitro and inhibited the growth of tumor xenografts in vivo. Our findings suggest that Skp2 levels are a key determinant of antitumor responses to mTOR inhibitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamycin as well as Skp2 silencing strategies for therapeutic purposes.",
author = "Hana Totary-Jain and Despina Sanoudou and Dautriche, {Cula N.} and Hillary Schneller and Lester Zambrana and Marks, {Andrew R.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-11-2195",
language = "English",
volume = "72",
pages = "1836--1843",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Rapamycin resistance is linked to defective regulation of Skp2

AU - Totary-Jain, Hana

AU - Sanoudou, Despina

AU - Dautriche, Cula N.

AU - Schneller, Hillary

AU - Zambrana, Lester

AU - Marks, Andrew R.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - The mammalian target of rapamycin (mTOR) plays a role in controlling malignant cellular growth. mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials. However, a significant number of tumors are rapamycin resistant. In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin. RNA interference (RNAi)-mediated silencing of Skp2 in human tumor cells increased their sensitivity to rapamycin in vitro and inhibited the growth of tumor xenografts in vivo. Our findings suggest that Skp2 levels are a key determinant of antitumor responses to mTOR inhibitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamycin as well as Skp2 silencing strategies for therapeutic purposes.

AB - The mammalian target of rapamycin (mTOR) plays a role in controlling malignant cellular growth. mTOR inhibitors, including rapamycin (sirolimus), are currently being evaluated in cancer trials. However, a significant number of tumors are rapamycin resistant. In this study, we report that the ability of rapamycin to downregulate Skp2, a subunit of the ubiquitin protein ligase complex, identifies tumors that are sensitive to rapamycin. RNA interference (RNAi)-mediated silencing of Skp2 in human tumor cells increased their sensitivity to rapamycin in vitro and inhibited the growth of tumor xenografts in vivo. Our findings suggest that Skp2 levels are a key determinant of antitumor responses to mTOR inhibitors, highlighting a potentially important pharmacogenomic marker to predict sensitivity to rapamycin as well as Skp2 silencing strategies for therapeutic purposes.

UR - http://www.scopus.com/inward/record.url?scp=84859396875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859396875&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2195

DO - 10.1158/0008-5472.CAN-11-2195

M3 - Article

C2 - 22311674

AN - SCOPUS:84859396875

VL - 72

SP - 1836

EP - 1843

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 7

ER -